Early Patterns of Sofosbuvir Utilization by State Medicaid Programs

Abstract

To the Editor: The cure rates associated with sofosbuvir, a new treatment for hepatitis C virus (HCV), have been remarkable. 1 However, the high cost of the drug has raised concerns, 2 particularly in regard to socioeconomically disadvantaged populations with a high prevalence of HCV infection, such as Medicaid beneficiaries. Demand for new HCV drugs in Medicaid populations drove historic surges in spending on drugs in 2014, the first full year during which sofosbuvir was available since its approval by the Federal Drug Administration (FDA) in late 2013. 3 Given its recent introduction to the market, little is known about state-level utilization and . . .